Parkinson DiseaseWalkingTall-PDNCT04613141
The WalkingTall Study: Comparing WalkingTall With Parkinson's Disease (WalkingTall-PD) With Mobility-plus to Reduce Falls and Improve Mobility.
A study testing WalkingTall-PD and Mobility-plus in people with Parkinson Disease, run by Neuroscience Research Australia at 1 site in Australia.
Trial summary
The purpose of this study is to determine and compare the effectiveness of WalkingTall-PD (the new intervention) against Mobility-plus (a PD appropriate exercise program) with respect to stabilizing gait, reducing step-time variability, preventing falls and enhancing independence in people with Parkinson's disease. Read more about this study
- Who is it for?
- Ages 40 years and older
- Conditions the study is for
- Parkinson Disease
- What is being tested?
- WalkingTall-PD and Mobility-plus
- Type of treatment
- Pill or oral medicine, Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 62 participants
- Where
- 1 siteAustralia
- Study dates
- 15 Jul 2021to 28 Sep 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Have been diagnosed with idiopathic Parkinson's disease (according to UK PD Society Brain Bank Criteria);
- Mild to severe (Hoehn and Yahr stage 1-4 idiopathic Parkinson's disease;
- Ability to walk 18 meters with or without an aid;
- At least one fall in the past 6 months, or at least 2 falls in the past 12 months, or severe mobility impairment such as freezing of gait, or history of near falls.
- Being stable on anti-Parkinsonian medications for > 1 month;
- Living independently in the community or retirement village;
- Able to communicate in English language.
Who cannot join
- Diagnosis of other neurological and/ or significant cognitive impairments (Montreal Cognitive Assessment < 19 points);
- Atypical Parkinsonism;
- Less than 6 months post deep brain stimulation surgery;
- Excessively high fall rates (> 12 falls in the past 6 months);
- Insufficient foot/ ankle sensation;
- Do not speak English;
- Have another medical condition besides Parkinson's disease that significantly impairs mobility, balance or ability to exercise safely;
- Already participating in a different study to improve mobility or prevent falls.
Trial locations and contacts
1 site in 1 country.
Australia1 site
Neuroscience Research Australia
Randwick, New South Wales, 2031
About this study
Official title: A Phase II Randomised Controlled Trial Comparing Home-based Self-managed Rehabilitation Program Using eHealth Technologies (Called WalkingTall-PD) With a Low-intensity Exercise Program (Called Mobility-plus).
The purpose of this study is to determine and compare the effectiveness of WalkingTall-PD (the new intervention) against Mobility-plus (a PD appropriate exercise program) with respect to stabilizing gait, reducing step-time variability, preventing falls and enhancing independence in people with Parkinson's disease.
WalkingTall-PD is a novel neuro-rehabilitation program delivered through a tablet/smart phone and smart socks for people with Parkinson's disease that aims to improve mobility and reduce falls. WalkingTall-PD combines a variety of PD-specific rhythmic stimuli (auditory, visual and haptic cues) which are synchronised with high intensity stepping, walking and balance training.
Mobility-plus is a "pseudo placebo" comparator program using non-slip socks, a low intensity paper-based exercise program and health information specific to Parkinson's Disease.
Read the detailed description
WalkingTall-PD is designed to rehabilitate gait and balance in a minimum of 6-weeks (program progression and total duration is based on sessions completed). It uses affordable eHealth technologies (tablet, phone, smart socks or leg bands, depending on participant preference, with vibration motors, step mat and earbuds). Specific to Parkinson's disease (PD), it uses rhythmic cues to address excessive step-time variability, balance impairments and freezing of gait (FOG) (Henderson et al., 2017; Allen et al., 2013). The key aspect of this intervention is the stimulation provided by the smart socks/leg bands that vibrate. The stimulus duty cycle is synchronised with the participants walking gait to entrain neuromuscular signals and enhance sensorimotor integration. This results in an immediate improvement in motor control during gait, reduced movement variability and increased walking ability. The integration of our eHealth tools with home visits and telehealth appointments into a continuous user experience is another major strength of our program. Each component is introduced during 1:1 home visits and/or telehealth appointments to ensure standardization of the clinical trial and maximize the safety of participants. The home visits and/or telehealth appointments will be conducted by a trainer (physiotherapist or exercise physiologist with experience in working with people with PD).
WalkingTall-PD meets the urgent need for an effective, affordable and scalable self-managed eHealth solution for people with PD. It includes an evidence-based program to enhance independence and prevent falls. The scientific rationale and eHealth technology underpinning WalkingTall-PD are well tested. Our team has demonstrated that home-based approaches have high acceptability and adherence rates, shown that balance training can reduce fall-risk and that external cues can reduce step-time variability in people with PD. Participants may use their preferred devices (or devices we supply) to access WalkingTall-PD, which will be available across platforms. Components are introduced during 1:1 home visits and telehealth appointments by a trainer. Delivery is then unsupervised using self-management principles, with ongoing remote monitoring a web-based central monitoring platform and database back-end.Participants will be informed that WalkingTall-PD is a supplementary program and does not replace usual care. The WalkingTall-PD program comprises the following components:
(i) Balance training is introduced in the week-one home visit or telehealth appointment by the trainer using the WalkingTall smart phone app. Baseline balance ability is determined by completing a series of balance exercises using the app with supervision from the trainer. For participants who choose the telehealth option, the primary device (smart phone) will provide the training program while a secondary device (iPad) will be used for patient safety monitoring and telehealth consultation. Exercises include heel raises, postural transitions, reaching and stepping in different directions and holding poses that challenge balance. Props used include a mobile stand (primary device), a tablet stand for the secondary device, non-slip balance mat and chairs for support. Balance training starts with simple movement sequences and progresses to more challenging balance poses based on participant feedback. Movements during balance training are guided by the combination of haptic cues provided by the smart socks, insoles or ankle bands(with the choice of smart garment based on participant preference), auditory cues by the phone app and visual cues by the balance/stepping mat. Participants will be encouraged to complete 5 by 10-minutes balance training sessions/week. Participants who choose the telehealth option will be provided with a home visit if they have difficulty with the balance training.
(ii) Walk training (in a safe environment) is introduced in the second home visit or telehealth appointment (no sooner than week-3) by the trainer using our WalkingTall phone app. Participant-adjustable rhythmic cues (Brodie et al., 2015) auditory, visual and haptic cues are used to reduce gait variability during gait training. Participants are instructed how to select an appropriate walking course (clear of trip hazards and with appropriate rest areas), target cadence and training/rest duration by the trainer. The walking course will be approved by the trainers, either in person or remotely via video recording if the participant chooses the telehealth option. For participants included in the telehealth option, if the trainer has concerns about the selected walking track, a home visit will be provided to fix any safety issues. Each session, consists of 5 by 2-minutes walks with 30-seconds rest between each walk. Rhythmic auditory cues (self-selected metronome) are provided by the phone app and earbuds can be used for discretion. Rhythmic haptic cues are provided by the smart socks, insoles or smart ankle bands, with the choice of smart garment based on participant preference. Participant-specific visual cues may also be used, if required, such as parallel lines fixed perpendicular to the walking track to step over. Participants will be instructed to use their normal walking aids as appropriate. Participants will be encouraged to complete 5 by 10-minute walk training in addition to the 5 by 10-minute balance training sessions each week. Participants who choose the telehealth option will be provided with a home visit if they have difficulty with the walk training.
(iii) Step training is introduced in the third home visit or telehealth appointment (no sooner than week-5) by the trainer using the WalkingTall phone app. Visual, auditory and haptic cues are synchronized with the movement to retrain impaired stepping (Caetano et al., 2018), turning, balance (Allen et al., 2013) and strength in people with PD. Auditory stepping cues are provided by the phone app using a metronome beat. Visual cues are provided by the non-slip stepping mat. Haptic stepping cues are provided by small vibrators. Participants will be encouraged to complete 5 by 10-minute step/strength training, 5 by 10-minute walk training and 5 by 10-minute balance training sessions each week. In week-5 the trainer will also introduce walk training in more complex environments or walking as part of normal daily-life activities as appropriate. Participants who choose the telehealth option will be provided with a home visit if they have difficulty with the step and training.
(iv) Post intervention. Reassessment will occur at 3-months. (v) Continuity of care is is provided by WalkingTall-PD using the WalkingTall phone app to self-manage any ongoing gait and balance impairments. Following the reassessment, participants will receive another home visit or telehealth consultation where an individualised program will be prescribed based on participant preference. For the remainder of the 3-months, participants will then be encouraged to complete at least 3 sessions per week of their individually prescribed WalkingTall-PD program. Training targets will be set and reviewed via monthly teleconferences and using the WalkingTall Study "Monthly Progress Chart". A study hotline is provided.
Mobility-plus is a "pseudo placebo" comparator program. It is not a true placebo because participants will be aware of which program they are in. However, both programs comprise of components that have potential to improve mobility and reduce falls risk and participants will not be informed of our hypothesis that WalkingTall-PD will be more effective than Mobility-plus. Participants in the Mobility-plus group will also be provided with gait-specific exercise equipment (two pairs of non-slips socks, which provide increased foot sensation through a pattern of raise non-slip nodules), a low intensity exercise program (3sessions per week) and health information specific to PD (included in the training manual). Participants will be informed that Mobility-plus is a supplementary program and does not replace usual care. The Mobility-plus program comprises the following components:
(i) Mobility exercises are introduced in week-1 by the trainer using the Mobility-plus exercise manual.Mobility-plus participants are provided with two pairs of non-slips socks and instructed to wear them while completing the Mobility-plus exercises. Participants use a chair as a prop and for balance support. Exercises include: (1) Standing hip abduction; (2) Standing knee flexion; (3) Seated knee extension; (4) Standing hip extension; and, (5) Standing hip flexion. Participants are instructed to complete 3-sets of 10-reps, for each exercise, for each leg, 3 times per week. Each session lasts approximately 10-minutes. For participants who choose the telehealth option this will be done via video conferencing and participants will be provided with a home visit if they have difficulty with the exercises.
(ii) Post intervention. Reassessment will occur at 3-months. (iii) Continuity of care is provided through the Mobility-plus manual. Participants will be encouraged to keep doing their Mobility-plus exercises 3 times per week for the remainder of the 3-month program. A study hotline is also provided for the Mobility-plus group.
- Conditions
- Parkinson Disease
- Being tested
- WalkingTall-PD, Mobility-plus
- Keywords
- Falls, Step-time variability, Freezing of Gait
- Medical subject headings
- Parkinson Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
WalkingTall-PDDevice
Smart garment (socks, insoles or ankle bands) delivering rhythmic haptic stimuli to the ankle timed with preferred cadence. Smart phone application delivers auditory cues synchronised with haptic stimuli. Smart phone application delivers a neurorehabilitation program.
Mobility-plusOther
Active 'pseudo placebo' comparator using a paper-based body weight exercise program.
| Study group | Role | What they receive |
|---|---|---|
| Mobility-plus | Sham comparator | Mobility-plus is a "pseudo placebo" comparator program using non-slip socks, a low intensity paper-based exercise program and health information specific to Parkinson's Disease. Receives: Other: Mobility-plus |
| WalkingTall-PD | Experimental | WalkingTall-PD is a novel neuro-rehabilitation program delivered through a tablet/smart phone and smart garments (socks, insoles or ankle bands) for people with Parkinson's disease that aims to improve mobility and reduce falls. WalkingTall-PD combines a variety of PD-specific rhythmic stimuli (auditory, visual and haptic cues) which are synchronised with high intensity stepping, walking and balance training. Receives: Device: WalkingTall-PD |
What is being measured
The primary outcome is the main question the study is designed to answer.
Gait variability (immediate effect of stimulation)
Standard deviation of step times will be assessed by a wearable device (McRoberts). This will be measured for both face-to-face and telehealth options. Baseline walking is compared to baseline walking with simulation (for the intervention group) and compared to walking with non-slip socks (for the control group). This will be repeated at 3-months. For face to face, gait variability will be assessed using the middle 16m of 4 x 20m straight line walks. For telehealth, it may not be possible to find a 20m straight line walking track, in which case more laps will be required to get a total distance of at least 80 meters. Regardless of the face to face or telehealth option, the same walking track will be used by each participant for each assessment to ensure consistency.
Measured: Baseline and 3-month re-assessment
Gait variability (no stimulation)
Standard deviation of step times will be assessed by a wearable device (McRoberts). This will be measured for both face-to-face and telehealth options. For both baseline and re-assessment the no stimulation condition is used. For face to face, gait variability will be assessed using the middle 16m of 4 x 20m straight line walks. For telehealth, it may not be possible to find a 20m straight line walking track, in which case more laps will be required to get a total distance of at least 80 meters. Regardless of the face to face or telehealth option, the same walking track will be used by each participant for each assessment to ensure consistency.
Measured: Baseline and 3-month re-assessment
Secondary outcomes (22)
Rate of falling
Rate of falling will be ascertained using weekly electronic falls calendars and email reminders. This will be measured for both face-to-face and telehealth options.
Measured: Baseline and post-intervention (3-months)
Levodopa equivalency daily dosage
This will be measured for both face-to-face and telehealth options.
Measured: Baseline and post-intervention (3-months)
Postural balance and mobility
Postural balance and mobility using the Mini-best test. This will be measured for both face-to-face and telehealth options. Although, this assessment will be adapted for telehealth purpose. Only items that are safer to be undertaken without a therapist support will be performed.
Measured: Baseline and post-intervention (3-months)
Physical activity enjoyment
Physical activity enjoyment will be assessed using Physical Activity Enjoyment Scale Questionnaire. This will be measured for both face-to-face and telehealth options.
Measured: Post-intervention (3-months)
System usability
System usability will be assessed using System Usability Scale Questionnaire. This will be measured for both face-to-face and telehealth options, and only for individuals who will receive the Walking-Tall PD training.
Measured: Post-intervention (3-months)
Attitudes to fall related intervention
Attitudes to fall related intervention will be assessed using Attitudes to Fall Related Intervention Scale Questionnaire. This will be measured for both face-to-face and telehealth options.
Measured: Post-intervention (3-months)
Exercise self-efficacy
Exercise self-efficacy will be assessed using Exercise Self-Efficacy Scale Questionnaire. This will be measured for both face-to-face and telehealth options.
Measured: Post-intervention (3-months)
Health-related quality of life
Health-related quality of life will be assessed using the European Quality of Life-5 EQ-5D. This will be measured for both face-to-face and telehealth options.
Measured: Baseline and post-intervention (3-months)
Parkinson's disease health status
Parkinson's disease health status using a PD-specific quality-of-life questionnaire. This will be measured for both face-to-face and telehealth options.
Measured: Baseline and post-intervention (3-months)
Lower extremity physical performance
Lower extremity physical performance will be assessed using the Short Physical Performance Battery. This will be measured for both face-to-face and telehealth options.
Measured: Baseline and post-intervention (3-months)
Parkinson's disease symptoms
Parkinson's disease symptoms will be assessed using the Movement Disorders Society - Unified Parkinson's Disease Rating Scale. This will be measured for both face-to-face and telehealth options. Although, this assessment will be adapted for telehealth purpose.
Measured: Baseline and post-intervention (3-months)
Freezing of gait
Freezing of gait will be assessed using the New Freezing of Gait Questionnaire. This will be measured for both face-to-face and telehealth options.
Measured: Baseline and post-intervention (3-months)
Concern about falling
Concern about falling will be assessed using the Iconographical Falls Efficacy Scale Questionnaire. This will be measured for both face-to-face and telehealth options.
Measured: Baseline and post-intervention (3-months)
Physical activity level
Activity levels will be assessed using the Incidental and Planned Exercise Questionnaire. This will be measured for both face-to-face and telehealth options.
Measured: Baseline and post-intervention (3-months)
Activity of daily living
Activities of daily living will be assessed using 1-week remote monitoring, including total steps/day, step-time variability, uninterrupted walk durations, falls, near falls and freezing of gait events. This will be measured for both face-to-face and telehealth options.
Measured: Baseline and post-intervention (3-months)
Exercise adherence
Exercise adherence will be assessed using monthly exercise calendars. An e-mail with a web link will be send to the participants, and they will be asked to report if any falls happened in a previous month. This will be measured for both face-to-face and telehealth options.
Measured: Post-intervention (3-months)
Health service use
Health service use will be assessed using a monthly questionnaire. This will be measured for both face-to-face and telehealth options.
Measured: Post-intervention (3-months)
Freezing of gait
Freezing of gait will be assessed by a wearable device during a freezing of gait elicitation protocol. This will be only measured for the face-to-face option.
Measured: Baseline and post-intervention (3-months)
Simple stepping ability
Simple stepping ability and reaction time will be assessed using the choice stepping reaction time test.
They will be only measured for face-to-face option.
Measured: Baseline (week 1) and post-intervention (7 weeks after randomisation).
Inhibitory stepping ability
Inhibitory stepping ability and reaction time will be assessed using the inhibitory choice stepping reaction time test.
They will be only measured for face-to-face option.
Measured: Baseline and post-intervention (3-months)
Complex stepping ability
Complex stepping ability and reaction time will be assessed using the stroop stepping test.
They will be only measured for face-to-face option.
Measured: Baseline and post-intervention (3-months)
Polypharmacy
Change in polypharmacy (the amount of medication taken). This will be measured for both face-to-face and telehealth options.
Measured: Baseline and post-intervention (3-months)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Nov 2020
- Study start15 Jul 2021
- Primary completion28 Sep 2022
- Study completion28 Sep 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Parkinson DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 62 participants (actual)
Sponsor and investigators
- Lead sponsor
- Neuroscience Research Australia
- Sponsor type
- University, hospital or other
- Collaborators
- Michael J. Fox Foundation for Parkinson's Research, Shake it up Australia Foundation, Sensoria Health Inc.
- Responsible party
- Sponsor
- Investigators
- Matthew A Brodie, Dr, Principal investigator, The University of New South Wales
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04613141
- Sponsor's protocol ID
- WalkingTallPD2019
- Acronym
- WalkingTall-PD
- Status last verified
- Oct 2022
- First submitted
- 27 Oct 2020
- Last updated
- 5 Oct 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Ernst M, Folkerts AK, Gollan R, Lieker E, Caro-Valenzuela J, Adams A, Cryns N, Monsef I, Dresen A, Roheger M, Eggers C, Skoetz N, Kalbe E. Physical exercise for people with Parkinson's disease: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2024 Apr 8;4(4):CD013856. doi: 10.1002/14651858.CD013856.pub3.
PubMed 38588457Ernst M, Folkerts AK, Gollan R, Lieker E, Caro-Valenzuela J, Adams A, Cryns N, Monsef I, Dresen A, Roheger M, Eggers C, Skoetz N, Kalbe E. Physical exercise for people with Parkinson's disease: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2023 Jan 5;1(1):CD013856. doi: 10.1002/14651858.CD013856.pub2.
PubMed 36602886
Study at a glance
From the registry record, last updated by the sponsor on 5 Oct 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase II Randomised Controlled Trial Comparing Home-based Self-managed Rehabilitation Program Using eHealth Technologies (Called WalkingTall-PD) With a Low-intensity Exercise Program (Called Mobility-plus).
- ClinicalTrials.gov ID
- NCT04613141
- Acronym / sponsor ID
- WalkingTall-PD / WalkingTallPD2019
- Conditions
- Parkinson Disease
- Keywords
- Falls, Step-time variability, Freezing of Gait
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 62 participants (actual)
- Lead sponsor
- Neuroscience Research AustraliaUniversity, hospital or other
- Collaborators
- Michael J. Fox Foundation for Parkinson's Research, Shake it up Australia Foundation, Sensoria Health Inc.
- Study start
- 15 Jul 2021 (actual)
- Primary completion
- 28 Sep 2022 (actual)
- Study completion
- 28 Sep 2022 (actual)
- First posted
- 3 Nov 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to determine and compare the effectiveness of WalkingTall-PD (the new intervention) against Mobility-plus (a PD appropriate exercise program) with respect to stabilizing gait, reducing step-time variability, preventing falls and enhancing independence in people with Parkinson's disease.
WalkingTall-PD is a novel neuro-rehabilitation program delivered through a tablet/smart phone and smart socks for people with Parkinson's disease that aims to improve mobility and reduce falls. WalkingTall-PD combines a variety of PD-specific rhythmic stimuli (auditory, visual and haptic cues) which are synchronised with high intensity stepping, walking and balance training.
Mobility-plus is a "pseudo placebo" comparator program using non-slip socks, a low intensity paper-based exercise program and health information specific to Parkinson's Disease.
Detailed description
WalkingTall-PD is designed to rehabilitate gait and balance in a minimum of 6-weeks (program progression and total duration is based on sessions completed). It uses affordable eHealth technologies (tablet, phone, smart socks or leg bands, depending on participant preference, with vibration motors, step mat and earbuds). Specific to Parkinson's disease (PD), it uses rhythmic cues to address excessive step-time variability, balance impairments and freezing of gait (FOG) (Henderson et al., 2017; Allen et al., 2013). The key aspect of this intervention is the stimulation provided by the smart socks/leg bands that vibrate. The stimulus duty cycle is synchronised with the participants walking gait to entrain neuromuscular signals and enhance sensorimotor integration. This results in an immediate improvement in motor control during gait, reduced movement variability and increased walking ability. The integration of our eHealth tools with home visits and telehealth appointments into a continuous user experience is another major strength of our program. Each component is introduced during 1:1 home visits and/or telehealth appointments to ensure standardization of the clinical trial and maximize the safety of participants. The home visits and/or telehealth appointments will be conducted by a trainer (physiotherapist or exercise physiologist with experience in working with people with PD).
WalkingTall-PD meets the urgent need for an effective, affordable and scalable self-managed eHealth solution for people with PD. It includes an evidence-based program to enhance independence and prevent falls. The scientific rationale and eHealth technology underpinning WalkingTall-PD are well tested. Our team has demonstrated that home-based approaches have high acceptability and adherence rates, shown that balance training can reduce fall-risk and that external cues can reduce step-time variability in people with PD. Participants may use their preferred devices (or devices we supply) to access WalkingTall-PD, which will be available across platforms. Components are introduced during 1:1 home visits and telehealth appointments by a trainer. Delivery is then unsupervised using self-management principles, with ongoing remote monitoring a web-based central monitoring platform and database back-end.Participants will be informed that WalkingTall-PD is a supplementary program and does not replace usual care. The WalkingTall-PD program comprises the following components:
(i) Balance training is introduced in the week-one home visit or telehealth appointment by the trainer using the WalkingTall smart phone app. Baseline balance ability is determined by completing a series of balance exercises using the app with supervision from the trainer. For participants who choose the telehealth option, the primary device (smart phone) will provide the training program while a secondary device (iPad) will be used for patient safety monitoring and telehealth consultation. Exercises include heel raises, postural transitions, reaching and stepping in different directions and holding poses that challenge balance. Props used include a mobile stand (primary device), a tablet stand for the secondary device, non-slip balance mat and chairs for support. Balance training starts with simple movement sequences and progresses to more challenging balance poses based on participant feedback. Movements during balance training are guided by the combination of haptic cues provided by the smart socks, insoles or ankle bands(with the choice of smart garment based on participant preference), auditory cues by the phone app and visual cues by the balance/stepping mat. Participants will be encouraged to complete 5 by 10-minutes balance training sessions/week. Participants who choose the telehealth option will be provided with a home visit if they have difficulty with the balance training.
(ii) Walk training (in a safe environment) is introduced in the second home visit or telehealth appointment (no sooner than week-3) by the trainer using our WalkingTall phone app. Participant-adjustable rhythmic cues (Brodie et al., 2015) auditory, visual and haptic cues are used to reduce gait variability during gait training. Participants are instructed how to select an appropriate walking course (clear of trip hazards and with appropriate rest areas), target cadence and training/rest duration by the trainer. The walking course will be approved by the trainers, either in person or remotely via video recording if the participant chooses the telehealth option. For participants included in the telehealth option, if the trainer has concerns about the selected walking track, a home visit will be provided to fix any safety issues. Each session, consists of 5 by 2-minutes walks with 30-seconds rest between each walk. Rhythmic auditory cues (self-selected metronome) are provided by the phone app and earbuds can be used for discretion. Rhythmic haptic cues are provided by the smart socks, insoles or smart ankle bands, with the choice of smart garment based on participant preference. Participant-specific visual cues may also be used, if required, such as parallel lines fixed perpendicular to the walking track to step over. Participants will be instructed to use their normal walking aids as appropriate. Participants will be encouraged to complete 5 by 10-minute walk training in addition to the 5 by 10-minute balance training sessions each week. Participants who choose the telehealth option will be provided with a home visit if they have difficulty with the walk training.
(iii) Step training is introduced in the third home visit or telehealth appointment (no sooner than week-5) by the trainer using the WalkingTall phone app. Visual, auditory and haptic cues are synchronized with the movement to retrain impaired stepping (Caetano et al., 2018), turning, balance (Allen et al., 2013) and strength in people with PD. Auditory stepping cues are provided by the phone app using a metronome beat. Visual cues are provided by the non-slip stepping mat. Haptic stepping cues are provided by small vibrators. Participants will be encouraged to complete 5 by 10-minute step/strength training, 5 by 10-minute walk training and 5 by 10-minute balance training sessions each week. In week-5 the trainer will also introduce walk training in more complex environments or walking as part of normal daily-life activities as appropriate. Participants who choose the telehealth option will be provided with a home visit if they have difficulty with the step and training.
(iv) Post intervention. Reassessment will occur at 3-months. (v) Continuity of care is is provided by WalkingTall-PD using the WalkingTall phone app to self-manage any ongoing gait and balance impairments. Following the reassessment, participants will receive another home visit or telehealth consultation where an individualised program will be prescribed based on participant preference. For the remainder of the 3-months, participants will then be encouraged to complete at least 3 sessions per week of their individually prescribed WalkingTall-PD program. Training targets will be set and reviewed via monthly teleconferences and using the WalkingTall Study "Monthly Progress Chart". A study hotline is provided.
Mobility-plus is a "pseudo placebo" comparator program. It is not a true placebo because participants will be aware of which program they are in. However, both programs comprise of components that have potential to improve mobility and reduce falls risk and participants will not be informed of our hypothesis that WalkingTall-PD will be more effective than Mobility-plus. Participants in the Mobility-plus group will also be provided with gait-specific exercise equipment (two pairs of non-slips socks, which provide increased foot sensation through a pattern of raise non-slip nodules), a low intensity exercise program (3sessions per week) and health information specific to PD (included in the training manual). Participants will be informed that Mobility-plus is a supplementary program and does not replace usual care. The Mobility-plus program comprises the following components:
(i) Mobility exercises are introduced in week-1 by the trainer using the Mobility-plus exercise manual.Mobility-plus participants are provided with two pairs of non-slips socks and instructed to wear them while completing the Mobility-plus exercises. Participants use a chair as a prop and for balance support. Exercises include: (1) Standing hip abduction; (2) Standing knee flexion; (3) Seated knee extension; (4) Standing hip extension; and, (5) Standing hip flexion. Participants are instructed to complete 3-sets of 10-reps, for each exercise, for each leg, 3 times per week. Each session lasts approximately 10-minutes. For participants who choose the telehealth option this will be done via video conferencing and participants will be provided with a home visit if they have difficulty with the exercises.
(ii) Post intervention. Reassessment will occur at 3-months. (iii) Continuity of care is provided through the Mobility-plus manual. Participants will be encouraged to keep doing their Mobility-plus exercises 3 times per week for the remainder of the 3-month program. A study hotline is also provided for the Mobility-plus group.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Mobility-plus | Sham comparator | Other: Mobility-plusMobility-plus is a "pseudo placebo" comparator program using non-slip socks, a low intensity paper-based exercise program and health information specific to Parkinson's Disease. |
| WalkingTall-PD | Experimental | Device: WalkingTall-PDWalkingTall-PD is a novel neuro-rehabilitation program delivered through a tablet/smart phone and smart garments (socks, insoles or ankle bands) for people with Parkinson's disease that aims to improve mobility and reduce falls. WalkingTall-PD combines a variety of PD-specific rhythmic stimuli (auditory, visual and haptic cues) which are synchronised with high intensity stepping, walking and balance training. |
Who may qualify
- Ages
- 40 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Have been diagnosed with idiopathic Parkinson's disease (according to UK PD Society Brain Bank Criteria);
- Mild to severe (Hoehn and Yahr stage 1-4 idiopathic Parkinson's disease;
- Ability to walk 18 meters with or without an aid;
- At least one fall in the past 6 months, or at least 2 falls in the past 12 months, or severe mobility impairment such as freezing of gait, or history of near falls.
- Being stable on anti-Parkinsonian medications for > 1 month;
Key exclusion criteria (8 listed)
- Diagnosis of other neurological and/ or significant cognitive impairments (Montreal Cognitive Assessment < 19 points);
- Atypical Parkinsonism;
- Less than 6 months post deep brain stimulation surgery;
- Excessively high fall rates (> 12 falls in the past 6 months);
- Insufficient foot/ ankle sensation;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| WalkingTall-PDSmart garment (socks, insoles or ankle bands) delivering rhythmic haptic stimuli to the ankle timed with preferred cadence. Smart phone application delivers auditory cues synchronised with haptic stimuli. Smart phone application delivers a neurorehabilitation program. | Device | WalkingTall-PD |
| Mobility-plusActive 'pseudo placebo' comparator using a paper-based body weight exercise program. | Other | Mobility-plus |
Primary outcome
Gait variability (immediate effect of stimulation)
Time frame: Baseline and 3-month re-assessment
Standard deviation of step times will be assessed by a wearable device (McRoberts). This will be measured for both face-to-face and telehealth options. Baseline walking is compared to baseline walking with simulation (for the intervention group) and compared to walking with non-slip socks (for the control group). This will be repeated at 3-months. For face to face, gait variability will be assessed using the middle 16m of 4 x 20m straight line walks. For telehealth, it may not be possible to find a 20m straight line walking track, in which case more laps will be required to get a total distance of at least 80 meters. Regardless of the face to face or telehealth option, the same walking track will be used by each participant for each assessment to ensure consistency.
Gait variability (no stimulation)
Time frame: Baseline and 3-month re-assessment
Standard deviation of step times will be assessed by a wearable device (McRoberts). This will be measured for both face-to-face and telehealth options. For both baseline and re-assessment the no stimulation condition is used. For face to face, gait variability will be assessed using the middle 16m of 4 x 20m straight line walks. For telehealth, it may not be possible to find a 20m straight line walking track, in which case more laps will be required to get a total distance of at least 80 meters. Regardless of the face to face or telehealth option, the same walking track will be used by each participant for each assessment to ensure consistency.
22 secondary outcomes
Rate of falling
Time frame: Baseline and post-intervention (3-months)
Levodopa equivalency daily dosage
Time frame: Baseline and post-intervention (3-months)
Postural balance and mobility
Time frame: Baseline and post-intervention (3-months)
Physical activity enjoyment
Time frame: Post-intervention (3-months)
System usability
Time frame: Post-intervention (3-months)
Attitudes to fall related intervention
Time frame: Post-intervention (3-months)
Exercise self-efficacy
Time frame: Post-intervention (3-months)
Health-related quality of life
Time frame: Baseline and post-intervention (3-months)
Parkinson's disease health status
Time frame: Baseline and post-intervention (3-months)
Lower extremity physical performance
Time frame: Baseline and post-intervention (3-months)
Parkinson's disease symptoms
Time frame: Baseline and post-intervention (3-months)
Freezing of gait
Time frame: Baseline and post-intervention (3-months)
Concern about falling
Time frame: Baseline and post-intervention (3-months)
Physical activity level
Time frame: Baseline and post-intervention (3-months)
Activity of daily living
Time frame: Baseline and post-intervention (3-months)
Exercise adherence
Time frame: Post-intervention (3-months)
Health service use
Time frame: Post-intervention (3-months)
Freezing of gait
Time frame: Baseline and post-intervention (3-months)
Simple stepping ability
Time frame: Baseline (week 1) and post-intervention (7 weeks after randomisation).
Inhibitory stepping ability
Time frame: Baseline and post-intervention (3-months)
Complex stepping ability
Time frame: Baseline and post-intervention (3-months)
Polypharmacy
Time frame: Baseline and post-intervention (3-months)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Oct 2022.
- Derived from this study: PubMed 38588457Ernst M, Folkerts AK, Gollan R, Lieker E, Caro-Valenzuela J, Adams A, Cryns N, Monsef I, Dresen A, Roheger M, Eggers C, Skoetz N, Kalbe E. Physical exercise for people with Parkinson's disease: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2024 Apr 8;4(4):CD013856. doi: 10.1002/14651858.CD013856.pub3.
- Derived from this study: PubMed 36602886Ernst M, Folkerts AK, Gollan R, Lieker E, Caro-Valenzuela J, Adams A, Cryns N, Monsef I, Dresen A, Roheger M, Eggers C, Skoetz N, Kalbe E. Physical exercise for people with Parkinson's disease: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2023 Jan 5;1(1):CD013856. doi: 10.1002/14651858.CD013856.pub2.
Related trials for Parkinson Disease
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Enrolling by invitationObservational study
Early Molecular Biomarkers for Differentiating Parkinsonian Syndromes
PARKINSON DISEASE (Disorder), Atypical Parkinsonism
RecruitingPhase 3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Cervical Cancer
Active, not recruitingPhase 1/2
Clinical Safety and Efficacy of Umbilical Cord Mesenchymal Stromal Cells-derived Exosomes in Patients With Parkinson's Disease
Parkinson Disease (PD)
Active, not recruitingObservational study
Adaptive DBS to Offset STN Dysregulation During Exercise in PD
Parkinson Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Matthew A Brodie, Dr principal investigator
The University of New South Wales
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing WalkingTall-PD and Mobility-plus in people with Parkinson Disease, run by Neuroscience Research Australia at 1 site in Australia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 Oct 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Australia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Gait variability (immediate effect of stimulation) (time frame: Baseline and 3-month re-assessment). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04613141, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Oct 2022.